• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类4Ig-B7-H3的分子特征,B7家族中具有四个免疫球蛋白样结构域的成员。

Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains.

作者信息

Steinberger Peter, Majdic Otto, Derdak Sophia V, Pfistershammer Katharina, Kirchberger Stefanie, Klauser Christoph, Zlabinger Gerhard, Pickl Winfried F, Stöckl Johannes, Knapp Walter

机构信息

Institute of Immunology, University of Vienna Medical School, Vienna, Austria.

出版信息

J Immunol. 2004 Feb 15;172(4):2352-9. doi: 10.4049/jimmunol.172.4.2352.

DOI:10.4049/jimmunol.172.4.2352
PMID:14764704
Abstract

In an effort to characterize molecules with immunoregulatory potential, we raised mAbs to human dendritic cells. We selected an Ab that recognizes a molecule that is induced on monocytes differentiated in vitro toward dendritic cells. Retroviral expression cloning identified this molecule as B7-H3, a member of the B7 family described recently. In contrast to an earlier report, in which B7-H3 was described as a molecule consisting of two Ig-like domains, our cDNA encoded a type I membrane protein with four Ig-like domains, and the molecule identified by us was therefore named 4Ig-B7-H3. mRNA analysis as well as Western blotting experiments performed by us did not reveal evidence for a small B7-H3. B7-H3 is not expressed on peripheral blood lymphocytes, monocytes, or granulocytes. Upon in vitro stimulation, the expression of B7-H3 is induced on T cells, B cells, and NK cells. A number of different approaches were used to investigate the function of human B7-H3. In contrast to an earlier report, our data do not support a costimulatory role of B7-H3 in anti-CD3-mediated activation of the TCR-complex resulting in T cell proliferation and IFN-gamma production.

摘要

为了鉴定具有免疫调节潜能的分子,我们制备了针对人树突状细胞的单克隆抗体。我们筛选出一种能识别在体外分化为树突状细胞的单核细胞上诱导产生的分子的抗体。逆转录病毒表达克隆鉴定该分子为B7-H3,它是最近描述的B7家族的一员。与之前将B7-H3描述为由两个免疫球蛋白样结构域组成的分子的报道不同,我们的cDNA编码一种具有四个免疫球蛋白样结构域的I型膜蛋白,因此我们鉴定的该分子被命名为4Ig-B7-H3。我们进行的mRNA分析以及蛋白质免疫印迹实验均未发现存在小B7-H3的证据。外周血淋巴细胞、单核细胞或粒细胞上均不表达B7-H3。在体外刺激后,T细胞、B细胞和NK细胞上会诱导B7-H3的表达。我们采用了多种不同方法来研究人B7-H3的功能。与之前的报道不同,我们的数据不支持B7-H3在抗CD3介导的TCR复合物激活中发挥共刺激作用从而导致T细胞增殖和产生γ干扰素。

相似文献

1
Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains.人类4Ig-B7-H3的分子特征,B7家族中具有四个免疫球蛋白样结构域的成员。
J Immunol. 2004 Feb 15;172(4):2352-9. doi: 10.4049/jimmunol.172.4.2352.
2
Characterization of mouse and human B7-H3 genes.小鼠和人类B7-H3基因的特征分析。
J Immunol. 2002 Jun 15;168(12):6294-7. doi: 10.4049/jimmunol.168.12.6294.
3
Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes.人外周血单核细胞上CD80(B7-1)和CD86(B7-2)的差异表达及功能
Immunology. 1996 Dec;89(4):592-8. doi: 10.1046/j.1365-2567.1996.d01-785.x.
4
Human recombinant B7-H3 expressed in E. coli enhances T lymphocyte proliferation and IL-10 secretion in vitro.在大肠杆菌中表达的人重组B7-H3可增强体外T淋巴细胞增殖和IL-10分泌。
Acta Biochim Biophys Sin (Shanghai). 2004 Jun;36(6):430-6. doi: 10.1093/abbs/36.6.430.
5
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.B7-H3:一种用于T细胞活化和干扰素-γ产生的共刺激分子。
Nat Immunol. 2001 Mar;2(3):269-74. doi: 10.1038/85339.
6
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.树突状细胞上的B7-H1(程序性死亡-1配体)参与T细胞无反应性的诱导和维持。
J Immunol. 2003 Apr 1;170(7):3637-44. doi: 10.4049/jimmunol.170.7.3637.
7
Murine B7-H3 is a negative regulator of T cells.小鼠B7-H3是T细胞的负调节因子。
J Immunol. 2004 Aug 15;173(4):2500-6. doi: 10.4049/jimmunol.173.4.2500.
8
B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction.B7-H3是人类T细胞活化的有效抑制剂:无证据表明B7-H3与TREML2相互作用。
Eur J Immunol. 2009 Jul;39(7):1754-64. doi: 10.1002/eji.200839028.
9
FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells.FDF03是一种免疫球蛋白超家族的新型抑制性受体,由人类树突状细胞和髓样细胞表达。
J Immunol. 2000 Aug 1;165(3):1197-209. doi: 10.4049/jimmunol.165.3.1197.
10
Cloning and characterization of porcine 4Ig-B7-H3: a potent inhibitor of porcine T-cell activation.猪 4Ig-B7-H3 的克隆与鉴定:一种有效的猪 T 细胞激活抑制剂。
PLoS One. 2011;6(6):e21341. doi: 10.1371/journal.pone.0021341. Epub 2011 Jun 27.

引用本文的文献

1
Computational structural optimization enhances IL13Rα2 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape.计算结构优化增强IL13Rα2 - B7-H3串联嵌合抗原受体T细胞以克服抗原异质性介导的肿瘤逃逸。
Mol Ther. 2025 Aug 8. doi: 10.1016/j.ymthe.2025.07.044.
2
Research progress of B7-H3 in malignant tumors.B7-H3在恶性肿瘤中的研究进展
Front Immunol. 2025 May 30;16:1586759. doi: 10.3389/fimmu.2025.1586759. eCollection 2025.
3
The relevance of B7-H3 and tumor-associated macrophages in the tumor immune microenvironment of solid tumors: recent advances.
B7-H3与肿瘤相关巨噬细胞在实体瘤肿瘤免疫微环境中的相关性:最新进展
Am J Transl Res. 2025 Apr 15;17(4):2835-2849. doi: 10.62347/ILTR3848. eCollection 2025.
4
Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution.精准靶向肺癌:抗体药物偶联物治疗变革
Curr Oncol Rep. 2025 Apr 16. doi: 10.1007/s11912-025-01655-5.
5
Challenges of small cell lung cancer heterogeneity and phenotypic plasticity.小细胞肺癌异质性和表型可塑性的挑战。
Nat Rev Cancer. 2025 Apr 10. doi: 10.1038/s41568-025-00803-0.
6
Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study.新型B7-H3嵌合抗原受体T细胞在胶质母细胞瘤中显示出强大的抗肿瘤作用:一项临床前研究。
J Immunother Cancer. 2025 Jan 25;13(1):e010083. doi: 10.1136/jitc-2024-010083.
7
Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.免疫检查点与非编码RNA:血液系统恶性肿瘤的开创性免疫治疗方法
Cancer Cell Int. 2024 Dec 19;24(1):410. doi: 10.1186/s12935-024-03596-8.
8
B7-H3 in glioblastoma and beyond: significance and therapeutic strategies.胶质母细胞瘤及其他疾病中的B7-H3:意义与治疗策略
Front Immunol. 2024 Nov 25;15:1495283. doi: 10.3389/fimmu.2024.1495283. eCollection 2024.
9
Advances in CAR-T therapy for central nervous system tumors.中枢神经系统肿瘤的嵌合抗原受体T细胞(CAR-T)疗法进展
Biomark Res. 2024 Nov 6;12(1):132. doi: 10.1186/s40364-024-00679-6.
10
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.胶质母细胞瘤中的免疫检查点途径:一个多样化且不断发展的领域。
Front Immunol. 2024 Sep 13;15:1424396. doi: 10.3389/fimmu.2024.1424396. eCollection 2024.